**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2016-2017/293

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | LAMIVUDINE, ZIDOVUDINE and NEVIRAPINE TABLETS 150 mg/200 mg/300 mg | | **REF. NO: NDQB201610186** |
| **DATE RECEIVED:** 25.10.2016 | **LABEL CLAIM:** | Each film-coated tablet contains Lamivudine USP 150 mg, Zidovudine USP 300 mg and Nevirapine USP 200 mg. | |
| **BATCH NO.:** X40541 | **PRESENTATION:** | White coloured, caplet shaped, biconvex faced tablets, embossed â€˜LZNâ€™ on one face and plain on the other packed in a white multidose plastic container of 60 tablets in a printed box. | |
| **MFG. DATE:** Jul. 2014 | **MANUFACTURER:** | CIPLA Ltd. | |
| **EXP. DATE:**  Jun. 2017 | **ADDRESS:** | Verna, Goa 403 722, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | Kenya Medical Supplies Authority, P. O. Box 47715 - 00100, Nairobi, KENYA. | |
| AZT/3TC/NVP/13/10/2016/209 | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPENDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2016 Vol. V App. XII C | NMT 2 tablets deviate by more than 5% from mean weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC | Adopted In-house Method | RT of the component peaks in the assay sample preparation correspond to those in the assay standard preparation | Super-imposable peaks at RT 2.9, 5.2 and 3.7 -/+ 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | Adopted In-house Method | No tablet less than 80.0% | Lamivudine 96.7%, (Range | **COMPLIES** |
| **Dissolution** |  |  |  | 96 - 98%) (RSD=0.7%; n=6) | **COMPLIES** |
| **Dissolution** |  |  |  | Zidovudine 96.5%, (Range | **COMPLIES** |
| **Dissolution** |  |  |  | 96 - 98%) (RSD=0.7%; n=6) |  |
| **Dissolution** |  |  |  | Nevirapine 98.8% (Range |  |
| **Dissolution** |  |  |  | 98 - 100%) (RSD=0.6%; n=6) |  |
| **Assay** | HPLC | Adopted In-house Method | 90.0 - 110.0% | Lamivudine 100.7% (RSD=1.0%; n=9) | **COMPLIES** |
| **Assay** |  |  |  | Zidovudine 101.5% (RSD=0.6%; n=9) | **COMPLIES** |
| **Assay** |  |  |  | Nevirapine 105.6% (RSD=0.8%; n=9) | **COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| **ANALYST:** | SARAH MWANGI | .......................................................... | DATE: 10-26-2016 |
| **REVIEWER** | DR. GEORGE WANG'ANG'A | .......................................................... | DATE: 25-10-2016 |
| **ANALYST:** | NICHOLAS MWAURA | .......................................................... | DATE: 11-25-2016 |
| **DIRECTOR:** | HEZEKIAH CHEPKWONY | .......................................................... | DATE: 11-29-2016 |